Clinical Trial Update: A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

A Phase 2 study of Danicopan for geographic atrophy due to age-related macular degeneration was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• Danicopan (danicopan)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Geographic Atrophy | Phase 2 | Status: TERMINATED | Results posted: 2025-09-05